Myomo, Inc. (MYO) Earnings Call Transcript
August 5, 2026
Earnings Call Speaker Segments
Thanks, operator, and good afternoon to everyone. I'm Vivian Cervantes, calling in from Alliance Advisors IR. I'd like to welcome all of you to the conference call covering Myomo's financial results for the second quarter of 2026. Joining me on today's call are Paul Gudonis, who serves as Myomo's Chief Executive Officer, along with Dave Henry, the company's Chief Financial Officer. Prior to getting started, I want to remind those listening that any remarks management makes on this call that aren't historical facts should be considered forward-looking statements. You'll typically see phrases such as anticipate, believe, estimate, expect, intend, guidance, outlook, confidence, target, project, and similar wording used to flag these kinds of forward-looking statements. Such forward-looking statements don't represent guarantees regarding future performance, and they could involve and are subject to risks, uncertainties, and additional factors that might impact Myomo's business, financial condition, and operating results. Those risks, uncertainties, and other factors get covered in the filings Myomo makes with the SEC. What actually happens and what results we achieve could differ materially from anything expressed or implied by these forward-looking statements. Also, unless the law requires it, Myomo accepts no obligation to revise or update any forward-looking statement to account for events or circumstances arising after today's call, which is August 5th, 2026. At this point, it's my pleasure to hand things over to Myomo CEO Paul Gudonis. Paul, the floor is yours.
Thank you, Vivian, and good afternoon to all of you. We appreciate everyone taking the time to be with us today. The mission we pursue at Myomo has not changed: we work to bring back function and independence for those who live with long-term paralysis affecting the arm and hand. Daily, we receive messages from patients whose lives the MyoPro has transformed — people who are now able to feed themselves again, pick up groceries, get back to their jobs, or just use both hands during ordinary tasks. That mission, together with our aim of reaching a far greater patient population, keeps shaping each choice we make. On the business side, the second quarter showed us making further headway on the plan we rolled out at the start of this year. Instead of leaning mainly on marketing aimed straight at consumers, we are constructing a business that is sturdier and can scale, by reshaping how we approach the market — placing emphasis on repeat patient referrals, broadening reimbursement coverage, keeping tight control over operational execution, and maintaining our lead in the market by innovating on our wearable robotics platform. Notably, across each of the four pillars of success I laid out at the beginning of this year, we are observing progress we can measure. Pillar one is our move toward recurring sources of patients. Second quarter total revenue rose 21% compared with the same period a year earlier, reaching $11.7 million, and sources of recurring patients accounted for 53% of overall revenue in that quarter. That figure is twice the 26% of revenue these sources contributed 12 months before. As we shift toward recurring patient sources, patient quality is getting better too. When it comes to turning referral leads into pipeline additions, the conversion rate is notably above what we see for leads generated through advertising. We brought on more than 150 referral sites, which takes us past 300 active locations, and a rising share of them are already sending us a second patient or more. O&P revenue came in at twice last year's level, and the national rollout of out-of-pocket care is moving along nicely while we hold talks with additional national O&P organizations. Pillar two is broadening market access. Under our national agreement, we have signed further Elevance state contracts, which widens our in-network presence. Among the other payer relationships we formed during the quarter, we now sit in network with the workers' compensation offering from Optum, which belongs to UnitedHealthcare. Being in network brings the advantage of greater authorization rates from payers we have contracts with. In a number of cases that remains modest but is expanding, authorization rates are coming in higher than those from payers without contracts, showing how much these agreements matter for better patient access and more efficient reimbursement. In the meantime, we keep serving a rising count of Medicare Part B patients, with a reimbursement rate of 100% for those whose complete medical documentation backs the delivery of a MyoPro to them. Pillar three is showing operating leverage. As noted, revenue was up 21% even though operating expenses rose just 1%. Our adjusted EBITDA came in more than $3 million better than in last year's second quarter. Revenue per employee keeps getting better as we bring in new systems and streamline our processes. Within our production group, we've established a Six Sigma team that's fully trained and actively carrying out efforts to cut costs. Those efforts include deploying mobile apps so that every device no longer requires spending on a laptop. Here in Burlington, Massachusetts, we're leveraging our new plant to bring in-house assembly work that used to go to outside contractors, and we've made a brand-new investment in 3D printing. Our confidence remains intact that these moves, along with others, will bring about wider margins and reduced cash burn. We're proving we can increase revenues more quickly than operating expenses, which places us on track toward profitability and cash flows that stay positive over the long term. Continued advancement in product development and clinical research forms our fourth success pillar. Work on the next generation, MyoPro 3, is proceeding according to plan. In May, at the OTWorld Conference held in Germany — Europe's biggest O&P industry gathering — we unveiled a hand-only prototype aimed at the German market, thereby broadening future market opportunities by addressing the patient group requiring just a hand function device. This stands as the newest illustration of how we build on our wearable robotics platform, which today features a cloud-based data collection system along with a mobile app for communicating with patients and clinicians. In the meantime, good progress is happening with the randomized control trial at the University of Utah, which has enrolled 25 out of 50 patients, and a publication with updated six-month outcomes is scheduled for the second half of this year. As you can observe, the key operating metrics keep heading in the right direction. We're expanding sources of recurring referrals, improving access to payers, demonstrating operating leverage, investing in innovation that's built on our platform, and most importantly, helping a greater number of patients get back the use of their arms and hands. As I wrap up my comments, here are a few additional highlights from the quarter. Our go-to-market approach has shifted toward recurring patient sources, and that change is delivering exceptional results — including a quarterly record of 255 MyoPro units ordered in Q2. One example of this strategy in action is Barbara, whose therapist at a big rehab hospital in New Jersey referred her to Myomo; she was going to receive therapy there after her stroke. Barbara came to our attention when her therapist contacted us, since she was 14 months past her stroke and her upper extremity gains had stopped improving. Her right arm was only minimally functional, so she was considered a possible MyoPro candidate. After an evaluation with favorable results, her doctor provided the necessary medical paperwork. Blue Cross Blue Shield, the insurer covering her, gave approval for the MyoPro 30 days after the assessment, and 90 days from the referral she had her custom-fitted MyoPro. Things are going well for her. Through therapy and training in how to operate her new MyoPro, she is making excellent progress. She can also benefit from the four-finger saddle we just launched, and that's going to support better functional grasp for daily living tasks, which she's now able to perform at home. What happened with Barbara really illustrates the effectiveness of our patient referral program — it links rehabilitation providers who see patients repeatedly directly at the point of care, helping people recover mobility and independence faster, and that has the potential to accelerate the revenue cycle. I'd also like to highlight that we made our board stronger by adding Joe Manko of Horton Capital, one of our largest shareholders, as well as Will Febbo, who brings significant experience as an executive in healthcare and med tech. Adding directors who bring deep industry knowledge, financial know-how, and a demonstrated track record of creating shareholder value makes our governance framework and strategic capabilities stronger. Having covered that, I'll hand things over now to Dave Henry so he can walk through our financial results in more detail.
I appreciate that, Paul, and good afternoon to all of you. As Paul mentioned moments ago, our go-to-market evolution keeps building momentum, and I'm happy to share that we delivered yet another quarter of strong results on both the financial and operational fronts. Revenue in the second quarter of 2026 came in at $11.7 million, which is a 21% increase compared with the same period a year earlier. That growth came from two sources: a rise in average selling price, or ASP, and a greater volume of revenue units. For the quarter, ASP stood at roughly $55,500, which is about 2% higher than the prior year. We booked revenue on 211 MyoPro units, which represents a 19% gain over the second quarter of 2025. Now, looking at payer mix: Medicare Part B patients accounted for 50% of second quarter revenue, versus 56% a year earlier. Medicare Advantage plans made up 16% of second quarter revenue, compared with 20% in the same period last year. Our shift toward recurring patient sources kept accelerating throughout the quarter. Recurring patient sources accounted for 53% of second quarter revenue, versus 26% in the prior year quarter — which means we hit our goal of 50% of revenues from recurring patient sources six months ahead of schedule. Within those recurring channels, 23% of total revenue came from direct billing referrals through our MyoConnect program, up from 20% in the first quarter. We're also still seeing solid momentum from our other recurring channels: international revenue made up 17% of revenue and grew 32% year-over-year, while the U.S. O&P channel accounted for 10% of revenue and grew 130% year-over-year. VA patients represented 3% of revenue in the second quarter. Moving to our metrics: we received a record 255 MyoPro orders in the quarter, a 23% increase year-over-year. Better conversion of orders into revenue speaks to how efficiently our operations run, since 57% of second quarter revenue units came from orders received during the quarter; we added 739 patients to the pipeline during the quarter, up 2% sequentially. Advertising spending rose 11% sequentially. Pipeline adds in the quarter took a hit from maintenance activities on our website, which caused a temporary pause in data sharing with our digital ad agency. Those activities are now finished and the website is working as it should. Patient quality in the pipeline is getting better, though, since 17% of pipeline adds in the second quarter came from direct billing referrals — which reflects our progress in adding referring sites and marks an 11% increase from the first quarter. To show what MyoConnect can do: typically, around 25% of our pipeline adds on a quarterly basis are Medicare patients. If you look only at MyoConnect pipeline adds so far in 2026, approximately 50% of patients entering the pipeline are Medicare patients. So as a result, growing direct billing referrals, together with our ongoing market access efforts, are boosting patient quality and are beginning to produce a higher authorization rate too. We closed the quarter with a backlog of 218 patients, down slightly from the first quarter, since higher revenue velocity offset stronger order growth. Now for our financial results. For Q2, gross margin came in at 72.1%, compared with 62.7% during the same period a year earlier. A few things drove that gain: a higher ASP, reduced overhead spending, and the positive effect from lower material costs, which includes the launch of the Myomo mobile app — partly offset by somewhat greater clinical costs that got reclassified into cost of goods sold. Operating expenses came to $10.7 million, which is an increase of under 1% versus the second quarter of 2025. Greater general and administrative expenses were offset by reduced advertising and R&D spending. Our operating loss showed major improvement, landing at $2.3 million versus $4.6 million in the prior year quarter. Adjusted EBITDA got better as well, moving to a loss of $800,000 from a loss of $4 million a year ago — that's a 79% improvement year over year. Keep in mind that part of that adjusted EBITDA gain stems from higher stock-based compensation expense, since some employee incentive payments were made in stock this quarter as part of our cash management initiatives. Beneath the operating loss line, Q2 results include a non-cash charge of roughly $1.2 million tied to a mark-to-market adjustment on the valuation of our derivative liabilities, plus cash and non-cash interest expense connected to the Avenue Capital term loan. Once those non-cash charges are factored in, net loss for the quarter totaled $4 million, or $0.09 a share, versus $4.6 million, or $0.11 per share, in the second quarter of 2025. Now let's look at our balance sheet and cash flow. At June 30th, 2026, cash equivalents and short-term investments come to $13.5 million. Cash used in operating activities for Q2 was $1.9 million — a big improvement from the $8.9 million used in the second quarter of 2025. Last year's cash burn took a hit from a temporary payment hold imposed by the DME MACs, along with 2024 incentive payments made in cash. Let me wrap up with our outlook. For Q3, we anticipate revenue landing between $11.5 million and $12 million, which works out to 14%-19% growth year over year. Because of the strong performance in the first half and ongoing momentum throughout the business, we're lifting our full year revenue guidance to $45 million-$47 million, up from the $43 million-$46 million we previously guided. We anticipate a modest sequential rise in operating expenses for Q3. We're also holding to the operating leverage objective we communicated before, which is to keep 2026 operating expense growth at half the rate of revenue growth. On top of that, we expect total cash burn in the back half of the year to come in under $2 million. All in all, we're quite happy with the progress being made. The way our go-to-market approach has evolved, the ongoing gains in operating leverage, and strong execution leave us well positioned for the rest of 2026. With that financial overview, I'll hand the call back to Paul.
Appreciate that, Dave. So to wrap up, we remain sharply concentrated on executing our 4 success pillars to expand MyoPro volume and revenues while also strengthening the important financial measures, such as gross margin, adjusted EBITDA, and cash usage. To date, more than 3,000 devices have been provided to patients, and our technology platform is transforming their lives in a major way. Even though we've built Myomo into the market leader tackling this substantial unmet need, we are still early in terms of penetrating the market, given a prevalence population of hundreds of thousands of qualified individuals dealing with chronic arm paralysis, plus tens of thousands more annually who pass through rehab clinics and could be potential MyoPro candidates too. Dave and I are prepared to answer your questions. Operator? As we wait for the first question, I want to note that during September, we will take part in the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 14 and 15. We'll be there in person at this conference and are open to one-on-one meetings. All right, operator, let's go ahead with the first question whenever you're ready.
Hey, everyone. Jake here, filling in for Chase. Nice work on the results. Appreciate you taking the questions; it's clear we're turning back toward growth at this point. Would you say MyoConnect is the main thing driving that? Are you noticing significantly better conversion rates among those patients who arrive via MyoConnect? And what share of the pipeline now consists of referrals from MyoConnect?
That's correct. The MyoConnect initiative is truly picking up speed in our view; we're expanding to as many as 300 referral sites. As Dave pointed out, what we're observing is that patients aren't just better qualified from a medical standpoint, since we've educated the therapists on who represents a strong MyoPro candidate, but they also generally carry superior insurance coverage. A bigger share of them are enrolled in Medicare Part B, which makes reimbursement for that patient simpler to obtain. That MyoConnect initiative is genuinely fueling our expansion. There are additional growth drivers I'd point to as well. Our O&P segment is expanding. In fact, we'll be attending the AOPA National Conference happening next month, where we'll keep cultivating relationships in that space. Europe is also experiencing strong growth; we have several growth drivers at work in that region. I believe Dave will address your question regarding the pipeline.
Right. Like I said, MyoConnect referrals accounted for 17% of the additions to our pipeline during the quarter. In the first quarter, that figure stood at 11%. I think that comes to roughly 122 referrals — referral pipeline additions.
Thanks a lot. Appreciate the additional detail. I’ll ask just one more question. What’s your view on when we’ll see readout timing for the Utah RCT, and assuming the data look good, what would be the main advantage you’d gain from it? Is the primary one growth in covered lives beyond Part B, or should we expect it to support demand generation in O&P and inside MyoConnect?
Well, for that second part, I'd say it's all of the above. I think we can work alongside our chief medical officer, approaching medical directors at different payers, and make the argument that, look, MyoPro isn't experimental or investigational. It's been proven. Medicare and other payers are covering it. Thousands of people are seeing benefits from it, and here's additional research data on it. Like I said, 25 of the 50 patient subjects are already enrolled in the study. We'll have a readout at six months, and we anticipate the full publication at some point in 2027.
Great. Thank you.
Thanks. Good afternoon. I'll begin with a few questions about the metrics. First, regarding the 255 orders, does that refer to the same thing that in the past was called authorizations?
Yes, it's the same.
All right, that's good.
Scott, what we see is a mix of insurance authorizations coming through our direct billing operation, plus orders, and POs that arrive from an O&P provider, or a PO from a VA.
All right. In the past, you provided the cumulative reimbursement pipeline figure. Does that number still exist, or will it be shared with us or not?
Yes. At the close of the quarter, the total pipeline stood at 1,491 patients.
All right. That number is somewhat smaller, though can you provide any explanation for it? I realize that on occasion you may remove certain individuals. It isn't ever a perfect comparison.
Yeah, I believe so. Keep in mind, given every one of the difficulties involved in attempting to secure authorizations for Medicare Advantage patients, many of them remain in the pipeline for some time. When considering pipeline additions, since those tend to be nearer, especially as we shift toward MyoConnect, I think that likely serves as a superior metric to examine rather than the total pipeline and whoever may be lingering there over a longer period. My suggestion would be to concentrate on the pipeline adds.
All right, I believe 739 was the figure in that spot. Would you say that figure works well?
739.
Okay. Would that figure make sense moving forward as a way to show expansion?
Correct. Like I said, those 739 contained 122 additions from the referral pipeline. As I noted, approximately 50% of MyoConnect pipeline additions during this year up to now are Medicare. That's compared to 25% across the entire program, which the advertising is responsible for. The patients we're observing under MyoConnect are far better, with fewer contraindications. Their lives are nearer to what they were before the stroke. Getting their reimbursement documents is simpler, and beyond that, a greater share of them fall under Medicare. That essentially sums up the reason behind our current approach.
All right; so, next year is a midterm election cycle, and from what I gather it will be quite an active one, which might crowd the media landscape and make it harder for you to communicate your message. Do you expect any effect from that during the second half of the year?
Generally speaking, in the fourth quarter each year, we usually reduce our direct-to-consumer advertising, partly for reasons like the ones you brought up, Scott. This time around, with it being an election year, there's greater competition for attention. On top of that, we have holiday advertising to contend with, and so forth; that's the reason we'll continue to focus on our MyoConnect program. We're increasing how many people we have in the field with sales and clinical expertise so we can establish additional referral sites, and that effort is largely unaffected by advertising considerations.
All right, that's good. So I suppose one last thing, looking at operating income, since I'm aware there's quite a bit of noise once you reach net loss. A $2.2 million figure for the quarter was a fairly solid quarter. Not many twos have shown up in that first digit. Do you figure we've reached a point now where it could even get better than this level? Or what's the right way to think about operating income on a sequential basis as the year progresses and beyond?
I suppose I'd sort of examine what makes it up. That might make the question simpler to respond to. Revenue guidance has been provided by us. On gross margin, 72% was where we stood. I can't see a reason it would decline. Reductions in cost keep moving quickly. Additional ones are in our plans, and those will bring manufacturing costs down in the second half of the year. Usually, revenues in the second half exceed those of the first half, so the leverage effect from that will come to us; regarding operating expenses, I mentioned expecting modest growth in operating expense during the third quarter. As for the fourth quarter, my expectation isn't for it to exceed the third. Along those same lines is where I'd expect it, I'd say. That ought to translate afterward into something like an improvement in operating loss as we move through the remainder, as we wrap up the year here with, presumably, based on our full-year guidance, that sort of results in greater fourth quarter revenue.
All right, that's helpful context — and thanks for fielding our questions.
Sure.
All right. Good afternoon, and thanks for taking my question. First off, on MyoConnect — you're still doing really well there with the referrals, and you're 6 months ahead of schedule to get above 50%, yet around 50% is still coming from direct consumer, direct-to-patient marketing. Could you maybe discuss how that's changed since the start of the year, and how you expect it to change over the remainder of 2026? How are you allocating your advertising dollars, your marketing dollars, within that bucket?
Yes. Part of the modest rise in operating expenses, I would expect, is a planned bump in ad spending during the third quarter, which is something we normally do before we ease off the gas on advertising spending somewhat in the fourth quarter. Advertising spending remains a key part of what we're doing, and revenues driven by advertising remain a key part of what we're doing. I simply want to ensure people realize we aren't shutting those off. On an ongoing basis, it will remain an important piece of our business; we just want to see a bigger mix of revenues coming from recurring patient sources.
All right, got it. In your view, where might that share of referrals, as opposed to your direct-to-consumer business, eventually level off?
As we head toward the close of the year, I'd say — we set a target of 50. A figure of 55% is likely a sensible level for us to finish the year at. Over a longer horizon, once MyoConnect begins to mature as we approach the end of the year, we may end up with something in the neighborhood of a 60/40 type of division, roughly along those lines.
All right, that's good. One final thing about the referral program — and I don't mean only MyoConnect, but also the O&P clinics and the VA. I'm confident you've already done your homework on this. What's the remaining runway? You mentioned having roughly 300 referrals — I'm not sure who exactly you refer them to — but these are referrals sending MyoPro patients your way. So how much runway is left? Just tell me the number of actual clinics you might sign, or O&P clinics either way.
Across the nation, stroke rehab clinics number in the several thousand, whether connected to large hospitals such as Spaulding Rehabilitation Hospital in Boston, or Kessler Rehabilitation Center, and others like them. Plenty of smaller neuro clinics nationwide treat stroke patients too. We're only at the beginning of this, and two growth factors apply to MyoConnect. First, deeper penetration — more awareness among therapists and physicians at these rehab clinics — and second, what I'd describe as same-store sales growth; we're already beginning to observe that following an initial referral, a second one comes. Ideally, with time, as they witness their patients gaining from the MyoPro, referrals per site will climb. In my view, two drivers here produce exponential growth. More sites referring, then more patients referred by each site as time goes on. It's the same story for the O&P clinics. Yes, O&P clinics. Out of the overall mix, revenue remains fairly small. O&P clinics nationwide number in the several thousand. We meet regularly with senior executives at those that have consolidated into national players; our aim is to boost penetration among their clinicians and offices while also continuing to locate additional entrepreneurial O&P clinics across the country. That's one more growth factor, not just within the U.S., but in Germany as well.
Excellent. All right, excellent. I really appreciate your time in answering my questions. I'll return to the queue.
Happy to help.
Yes. Congrats on everything you've accomplished. I'd like to ask about the international side. From what I hear, you plan to launch a hand-only device in Germany. Is Germany the only country where it will be sold, or do you also intend to make it available in the U.S.?
That's a really thrilling new product we're developing, and in May I traveled to Leipzig, Germany alongside our team to show off this prototype, which is still being worked on. Our decision to begin in Germany stems from the fact that a hand-only product qualifies for reimbursement there. A small rival called HKK is already on the market with a hand-only device. We're applying our technology platform to create a device that outperforms theirs. Since we're confident reimbursement will happen in Germany, that's where we're launching first. After that, we can figure out how to secure the right HCPCS codes in the U.S. so we can roll it out there as well, since there's clearly patient demand among those who retain upper arm movement but lack distal function. This product, built on our technology platform, would be offered and would broaden our addressable market.
Will this call for a lot of research and development spending, or have you already accounted for it within your operating expense projections?
That is something we'll be addressing as part of our OpEx planning. This isn't some big overhaul of the product. What it really involves is removing the <<inaudible>>, then putting the weight back in using fresh sensors along with power and unit components; set against the MyoPro 3, the R&D outlay here is fairly modest.
Excellent. Well, I appreciate it. Best of luck to all of you.
Very well. Thanks, Ed.
Alright, thanks to the operator, and I appreciate everyone being with us today as well as your questions; we're eager to see and hear from all of you over the next several months. Once more, thank you, and enjoy your evening.
That brings us to the end of today's conference call. At this point, you're free to disconnect your lines. We appreciate your participation, and we hope the rest of your day is a pleasant one.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Myomo, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Myomo, Inc. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.